Digital Hive Mind, a Rockford-based advertising and creative agency, was recently contracted by Taiho Oncology for product photography to support the launch of LYTGOBI tablets in the United States. Taiho Oncology, a subsidiary of Taiho Pharmaceutical Co. based in Tokyo, received marketing authorization from the FDA on September 30, 2022 for use of LYTGOBI in adult patients who suffer from metastatic intrahepatic cholangiocarcinoma (bile duct cancer within the liver).